Skip to main content

Gastrointestinal Stromal Tumor

  • Chapter
  • First Online:
Diagnostic Molecular Pathology in Practice
  • 2263 Accesses

Abstract

A 60-year-old female initially presented to a local urgent care center complaining of abdominal pain. Ultimately, an abdominal CT scan was obtained revealing a large upper abdominal mass of uncertain origin. The patient was referred to the regional academic medical center for possible surgical intervention. On evaluation, she complained of a two to three month history of early satiety, bloating, nausea, and intermittent abdominal pain. Her past medical history was significant for hypertension and hyperlipidemia. Her mother had been diagnosed with breast cancer at 62 years old, and there was no other family history of cancer. On physical examination, a left upper quadrant mass was palpable without associated tenderness. Review of the outside imaging confirmed a heterogeneous upper abdominal mass measuring 20 ?× ?17 cm. The origin of the tumor was difficult to ascertain but was considered possibly pancreatic or retroperitoneal. Laboratory data showed normal carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP) levels. An image-guided percutaneous needle biopsy was scheduled.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors (GISTs) of the stomach – a clinicopathologic, immunohistochemical and molecular genetic study of 1756 cases with long-term follow-up. Am J Surg Pathol 29:52–68

    Article  PubMed  Google Scholar 

  2. Dematteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled study. Lancet 373:1097–1104

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Corless CL, McGreevey L, Haley A et al (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567–1572

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Battochio A, Mohammed S, Winthrop D et al (2010) Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors – comparison of DHPLC and DNA sequencing methods using a single population-based cohort. Am J Clin Pathol 133:149–155

    Article  PubMed  CAS  Google Scholar 

  5. Holden JA, Willmore-Payne C, Coppola D et al (2007) High-resolution melting amplicon analysis as a method to detect c-KIT and platelet derived growth factor receptor ? activating mutations in gastrointestinal stromal tumors. Am J Clin Pathol 128:230–238

    Article  PubMed  CAS  Google Scholar 

  6. Sciot R, Debiec-Rychter M, Daugaard S et al (2008) Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): an analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. Eur J Cancer 44:1855–1860

    Article  PubMed  Google Scholar 

  7. Heinrich MC, Maki RG, Corless CL et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352–5359

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Heinrich MC, Owzar K, Corless CL et al (2008) Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALBG 150105 study by cancer and leukemia group B and southwest oncology group. J Clin Oncol 26:5360–5367

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Lasota J, Miettinen M (2008) Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53:245–266

    Article  PubMed  CAS  Google Scholar 

  10. Bachet J, Hostein I, Le Cesne A et al (2009) Prognosis and predictive value of KIT exon 11 deletion in GISTs. Br J Cancer 101:7–11

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Lasota J, Corless CL, Heinrich MC et al (2008) Clinico­pathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 21:476–484

    Article  PubMed  CAS  Google Scholar 

  12. Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer 42:1093–1103

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jennifer Laudadio .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Laudadio, J. (2011). Gastrointestinal Stromal Tumor. In: Schrijver, I. (eds) Diagnostic Molecular Pathology in Practice. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19677-5_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-19677-5_26

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-19676-8

  • Online ISBN: 978-3-642-19677-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics